限制性液体复苏较标准治疗降低脓毒性休克患者病死率与器官功能障碍发生率
本研究纳入238例需液体复苏的脓毒性休克连续患者,按初始复苏阶段液体管理方式分为限制性组与标准液体管理组,比较病死率与器官功能障碍。限制性液体管理占59.2%,标准液体管理占40.8%。限制性复苏组住院病死率更低(24.8% vs 52.6%),中位ICU住院时间更短(8.0天 vs 11.0天),新发急性肾损伤发生率(25.5% vs 51.5%)和肾脏替代治疗发生率(20.6% vs 40.2%)更低。多因素logistic回归显示限制性液体管理(OR 0.312,95%CI 0.098-0.994)和无血管升压药天数(OR 0.807,95%CI 0.765-0.851)为住院死亡的保护因素,APACHE II评分(OR 1.121,95%CI 1.018-1.234)为独立危险因素。作者认为限制性液体复苏联合早期血管升压药方案可行且安全。
要点
- 238例脓毒性休克连续患者中,限制性液体复苏组住院病死率24.8%,标准液体管理组52.6%。
- 限制性组中位ICU住院时间8.0天,短于标准组的11.0天。
- 限制性组新发急性肾损伤25.5%、肾脏替代治疗20.6%,分别低于标准组的51.5%和40.2%。
- 多因素logistic回归:限制性液体管理OR 0.312(95%CI 0.098-0.994)、无血管升压药天数OR 0.807(95%CI 0.765-0.851)为住院死亡保护因素;APACHE II评分OR 1.121(95%CI 1.018-1.234)为独立危险因素。
- 标准组需要机械通气的风险更高,无呼吸机中位天数显著少于限制性组;限制性组无血管升压药中位天数25.0天,长于标准组的18.0天。
适用人群与场景
- 需要液体复苏的脓毒性休克连续患者,共238例。
处置流程与药物剂量
- 按初始复苏阶段液体管理方式分为限制性液体管理组(59.2%)与标准液体管理组(40.8%)。
- 限制性液体复苏联合早期血管升压药方案。
研究设计与关键结果
- 研究类型为连续患者的分组比较研究,共纳入238例脓毒性休克患者;限制性液体管理59.2%,标准液体管理40.8%。
- 主要终点住院病死率:限制性组24.8% vs 标准组52.6%。
- 中位ICU住院时间:限制性组8.0天 vs 标准组11.0天。
- 新发急性肾损伤:限制性组25.5% vs 标准组51.5%;肾脏替代治疗:限制性组20.6% vs 标准组40.2%。
- 标准组需要机械通气的风险更高,无呼吸机中位天数显著低于限制性组。
- 无血管升压药中位天数:限制性组25.0天 vs 标准组18.0天,限制性组显著更长。
- 正性肌力药使用率:限制性组显著低于标准组。
- 多因素logistic回归:限制性液体管理OR 0.312(95%CI 0.098-0.994)、无血管升压药天数OR 0.807(95%CI 0.765-0.851)为住院死亡的保护因素;APACHE II评分OR 1.121(95%CI 1.018-1.234)为住院死亡的独立危险因素。
证据类型、等级与局限
- 证据类型:连续患者的分组比较研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,脓毒性休克患者采用限制性液体复苏联合早期血管升压药方案与更好的结局相关,该方案可行且安全。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Background : The influence of restrictive fluid resuscitation and the early administration of vasopressors on the clinical outcomes in patients with septic shock are not fully understood. The purpose of this study was to evaluate the effects of restrictive fluid management on mortality and organ dysfunction in patients with septic shock. Methods : This study included consecutive patients with septic shock in need of fluid resuscitation. Based on the fluid management provided in the initial resuscitation phase, a comparison was made between a restrictive group and a standard fluid management group. The primary outcome was in-hospital death, whereas secondary outcomes included organ dysfunction and other adverse events. Results : A total of 238 patients were included in this study. Restrictive fluid management was administered to 59.2% of patients, whereas 40.8% received standard fluid management. Restrictive resuscitation was associated with a lower in-hospital mortality rate (24.8% vs. 52.6%), as well as a shorter median intensive care unit stay (8.0 vs. 11.0 days). The restrictive strategy was associated with a significantly lower prevalence of new-onset acute kidney injury (25.5% vs. 51.5%) and a decrease in the incidence of renal replacement therapy (20.6% vs. 40.2%). The standard group had a higher risk of the need for mechanical ventilation and a significantly lower median number of days without a ventilator than the restrictive group. The median duration of vasopressor-free days in the restrictive group was significantly longer than that in the standard group (25.0 vs. 18.0). The administration rate of inotropes in the restrictive group was significantly lower than that in the standard group. A multivariate logistic regression model showed that restrictive fluid management (odds ratio [OR], 0.312; 95% confidence interval [CI], 0.098-0.994) and vasopressor-free days (OR, 0.807; 95% CI, 0.765-0.851) protect against in-hospital death, whereas Acute Physiology and Chronic Health Evaluation II scores (OR, 1.121; 95% CI, 1.018-1.234) were independent risk factors for in-hospital death. Conclusions : Restrictive fluid resuscitation and early vasopressor protocol in patients with septic shock are associated with better outcomes, indicating that this regimen is feasible and safe.
参考来源
- Jiang Z, Luo F, Liu Y, et al. RESTRICTIVE FLUID RESUSCITATION IN SEPTIC SHOCK PATIENTS HAS LOWER MORTALITY AND ORGAN DYSFUNCTION RATES THAN STANDARD THERAPY. Shock. 2023. PMID: 37962948. doi:10.1097/SHK.0000000000002235
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。